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were updated to € 2013. Results: The primary analysis compared dapagliflozin 
with sulfonylureas resulting in 0.525 additional QALYs and € 1,835 additional cost 
(cost-effectiveness ratio of € 3,496/QALY). The higher drug cost of dapagliflozin was 
partially offset by lower costs of complications, hypoglycemia and the cost associ-
ated with weight gain. In the secondary analyses, dapagliflozin was a cost-effective 
option compared with thiazolidinediones and DPP4, resulting in a cost per QALY 
gained of € 20,183 and € 487, respectively. The univariate and probabilistic sensitivity 
analyses confirmed the robustness of the results. ConClusions: Dapagliflozin in 
combination with metformin proved to be a cost-effective alternative compared to 
sulfonylureas, thiazolidinediones and DPP4 inhibitors in the treatment of T2DM.
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objeCtives: Diabetes is a chronic disease and associated with significant health 
care expenditures. Increasing costs are mainly related to long-term complications. 
Identifying patterns of hypoglycemia by means of a blood glucose monitoring sys-
tem (BGMS) can be used to support diabetes management efficiently. Methods: 
An economic analysis was carried out to estimate the life-time cost-effectiveness 
(CEA) of blood glucose monitoring system (BGMS) with pattern alert technology vs. 
standard BGMS for the prevention of Severe Hypoglycaemia (SH) in insulin-treated 
type 1 (DM1) and type 2 patients (DM2). The cost-effectiveness analysis was based 
on a literature review and cost data (direct and indirect) from the Emilia Romagna 
region; a decision tree was developed to calculate the incremental cost per addi-
tional quality of life. The BIA (Budget Impact Analysis) estimated the cost of using 
the new pattern alert technology in the Italian Healthcare System. Results: For 
the base-case scenario, the utilization of BGMS with pattern alert technology was 
less costly and more effective compared to standard BGMS. Life time cost savings 
for the prevention of SH were 300 euro for DM1 and DM2 patients using pattern 
alert technology. The difference in life time QALYs was 0,17. ConClusions: BGMS 
with pattern alert technology, monitoring individual blood glucose levels are cost 
effective in preventing SH for DM1 and insulin-treated DM2 patients, as well as in 
detecting blood glucose trends and patterns. Nevertheless, empirical data on the 
probability of reducing Severe Hypoglycemia is necessary in order to reach any 
firm conclusions.
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objeCtives: Diabetes mellitus represents a significant challenge to health care 
providers in Spain, with a national prevalence of over 8% and approximately 20,000 
diabetes-related deaths annually. Treatment with GLP-1 receptor agonists and DPP-4 
inhibitors, which target the incretin axis, has the potential to improve glycemic 
control without the weight gain associated with traditional therapies. To evaluate 
the relative cost-effectiveness of incretin therapies, the present study compared the 
long-term clinical and cost implications associated with liraglutide and sitagliptin in 
type 2 diabetes patients in Spain. Methods: Data were taken from a randomized, 
controlled trial (NCT00700817) in which adults with type 2 diabetes (mean age 55 
years, HbA1c 8.4%, BMI 33kg/m2) failing metformin monotherapy were randomly 
allocated to receive either 1.2mg liraglutide or 100mg sitagliptin daily in addition 
to metformin. Liraglutide was associated with greater improvements from baseline 
HbA1c (–1.24% vs. –0.9%) and BMI (–0.99kg/m2 vs. –0.33kg/m2). Long-term projec-
tions of clinical outcomes and direct costs (2012 EUR) were made using a published 
and validated model of type 2 diabetes and assumed patients switched to insulin 
after five years. Results: Liraglutide was associated with improved life expec-
tancy (14.05 years vs. 13.91 years) and quality-adjusted life expectancy (9.04 quality-
adjusted life years [QALYs] vs. 8.87 QALYs) compared to sitagliptin. Improved clinical 
outcomes were driven by improved glycemic control, leading to a reduced incidence 
of diabetes-related complications, including renal disease, cardiovascular disease, 
ophthalmic and diabetic foot complications. Mean cost savings as a result of avoided 
complications were EUR 1,827 per patient. Overall, liraglutide was associated with 
increased direct costs of EUR 2,297, yielding an incremental cost-effectiveness ratio 
of EUR 13,266 per QALY gained versus sitagliptin. ConClusions: Liraglutide was 
projected to improve life expectancy, quality-adjusted life expectancy and reduce 
incidence of diabetes-related complication. Liraglutide is likely to be cost-effective 
from a health care payer perspective in Spain.
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objeCtives: To project the long-term costs and outcomes of continuous subcu-
taneous insulin infusion (CSII) compared with multiple daily injections (MDI) in 
children with Type 1 diabetes in KAZAKHSTAN. Methods: The CORE Diabetes 
Model is a peer-reviewed, validated model, which employs standard Markov/Monte 
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objeCtives: To project the long-term costs and outcomes of continuous sub-
cutaneous insulin infusion (CSII) compared with multiple daily injections (MDI) 
in adult patients with Type 1 diabetes in KAZAKHSTAN. Methods: The CORE 
Diabetes Model is a peer-reviewed, validated model, which employs standard 
Markov techniques to describe the long-term incidence and progression of diabe-
tes-related complications. It was used to simulate disease progression in a cohort 
of adult patients with baseline characteristics and costs taken from primary data 
collection in KAZAKHSTAN (mean age 39.7 years, duration of diabetes 10.1 years 
and mean HbA1c 8.5%). Clinical outcomes (HbA1c and hypoglycemic events) were 
taken from a published meta-analysis of CSII studies. Direct costs for 2013 were 
calculated from a third-party payer perspective. Discount rates of 5% per annum 
were applied to costs and 3% to clinical outcomes. Results: Treatment with CSII 
was associated with an improvement in mean quality adjusted life expectancy 
(QALE) of 0.745 years compared with MDI and incidence of any diabetes related 
complication was delayed on average by 1 year with CSII. This produced an incre-
mental cost-effectiveness ratio (ICER) of KZT 4’784’971 per quality-adjusted life 
year (QALY) gained with CSII vs. MDI. CSII related therapy costs were partially 
offset by the savings due to the reduction in long-term complications. CSII treat-
ment also delayed the average onset of complications such as ESRD (1.9 years) and 
blindness (2.1 years). Extensive sensitivity analyses showed the robustness of the 
results. ConClusions: Improvements in glycemic control associated with CSII 
over MDI led to improved QALE owing to reduced incidence of diabetes-related 
complications. CSII was associated with ICERs representing good value for money 
by current standards in KAZAKHSTAN (using a WTP threshold of 6,330,000 KZT 
[3x GDP]) from a payer’s perspective. CSII would be even more attractive from a 
societal perspective when including indirect costs.
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objeCtives: Dapagliflozin (DAPA), a selective SGLT2 inhibitor, reduces hypergly-
caemia in an insulin-independent manner by increasing urinary glucose excretion. 
Glipizide (sulphonylurea) reduces hyperglycemia by increasing beta cell insulin 
secretion. We conducted an analysis of the cost of treating patients to a clinically 
relevant composite endpoint of HbA1c < 7%, no major or minor hypoglycaemic 
events and weight loss ≥ 3%. Methods: The Cardiff Diabetes model was used to 
estimate the cost of treating patients to the composite endpoint of HbA1c < 7%, 
no major or minor hypoglycaemic events and weight loss ≥ 3% in the UK using 
52 week data from a previously published double-blind randomised clinical trial 
of DAPA vs glipizide (GLIP) in combination with metformin (NCT 00660907). The 
cost of treating one patient to the composite endpoint using DAPA or GLIP over 
52 weeks was calculated as total cost per treatment arm divided by number of 
patients that reached the composite endpoint in that treatment arm. Calculation 
of costs included drug acquisition costs, cost for adverse events, and costs related 
to the patient’s BMI level. Results: The number needed to treat was 5 on DAPA 
and 54 on GLIP for one patient to achieve the composite endpoint. The overall cost 
of treating one patient over 52 weeks to the composite endpoint of HbA1c < 7%, no 
major or minor hypoglycaemic events and ≥ 3% weight loss was £3296 on DAPA 
and £13620 on GLIP. ConClusions: The cost of treating one patient to composite 
endpoint of HbA1c < 7%, no major/minor hypoglycaemic events and ≥ 3% weight 
loss was approximately 4 times higher with GLIP compared to DAPA. These results 
demonstrate that when multiple treatment goals, including weight loss and reduc-
tion of hypoglycaemic events are targeted, the cost of treating patients with DAPA 
is lower compared to GLIP.
PDB47
cost-effectIveness AnAlysIs of DAPAglIfozIn versus other t2Dm 
treAtments In the sPAnIsh context
Abad Paniagua E.J.1, Casado Escribano P.2, Fernández Rodriguez J.M.3, Morales Escobar F.J.4, 
Canal Fontcuberta C.5, Betegón Nicolás L.5, Capel M.6, Brosa M.7
1Centro de Salud las Águilas, Madrid, Spain, 2Hospital La Princesa, Madrid, Spain, 3HOSPITAL 
CARMEN Y SEVERO OCHOA, Asturias, Spain, 4Centro de Salud de Arucas, Gran Canrias, 
Spain, 5Bristol-Myers Squibb, Madrid, Spain, 6AstraZeneca, Madrid, Spain, 7Oblikue Consulting, 
Barcelona, Spain
objeCtives: To analyse the cost-effectiveness of dapagliflozin in combination with 
metformin in the treatment of type 2 diabetes (T2DM) in comparison with sulfo-
nylureas, thiazolidinediones and DPP4 inhibitors also combined with metformin 
in Spain. Methods: The analysis was based on the results of the available clinical 
trials in order to estimate the quality-adjusted life years (QALY) and economic con-
sequences of managing the disease and its complications. An economic model was 
used to simulate the natural history of 10,000 T2DM patients with each treatment 
option. The analysis was performed from the National Health System perspective 
considering direct costs (pharmacological costs, adverse events, T2DM complica-
tions, hypoglycaemias and costs related to weight gain) and patient’s entire life 
as time horizon. A discount rate of 3% was applied to costs and benefits. All costs 
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objeCtives: With new classes of T2DM medications offering weight reduction in 
addition to better glycaemic control, HTA agencies expect fuller accounting of the 
impact of post-trial weight trajectory assumptions on cost-effectiveness. Four alter-
native scenarios were examined using the example of the novel SGLT-2 inhibitor 
canagliflozin (CANA) in the UK treatment setting. Methods: The importance of 
alternative assumptions was illustrated using CANA 300mg versus glimepiride (GLIM; 
1mg titrated to 6mg or 8mg) in dual therapy with metformin simulated over 40 years 
using the ECHO-T2DM model loaded with patient characteristics, treatment effects, 
and adverse event rates from the DIA3009 trial, in which CANA 300mg reduced body 
weight by –5.7% versus GLIM over 52 weeks. HbA1c was assumed to drift annually by 
0.14% for CANA (similar to metformin in ADOPT), 0.24% for GLIM (as sulphonylurea 
in ADOPT), and 0.15% for rescue therapy with insulin (initiated when HbA1c > 7.5%). 
Upon treatment discontinuation, four alternative weight-trajectory assumptions were 
applied: (A) weight change maintained permanently; (B) CANA weight reduction dis-
appears fully at treatment discontinuation, GLIM weight-gain permanent; (C) GLIM 
weight-gain permanent, forced convergence of weight upon CANA discontinuation; 
(D) weight changes disappear fully at discontinuation for both treatments. A weight 
increase was applied when insulin was initiated and proportional weight changes 
were applied when insulin dose was titrated upwards. Results: CANA 300mg gener-
ated more QALYs at modest incremental cost, resulting in ICERs of £2,766 to £4,317 in 
the scenarios. Maintaining the benefits permanently (A) generated the largest QALY 
gain (0.243); complete elimination of benefits at discontinuation (D) offered the small-
est (0.198). The proportions of incremental QALYs attributable to weight differences 
were 34.4%, 19.5%, 18.9% and 17.4% for Scenarios A to D, respectively. ConClusions: 
CANA 300mg was cost-effective in each of four weight scenarios following discon-
tinuation. Further work is required to define the most clinically plausible scenarios.
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objeCtives: Dapagliflozin (Forxiga®) is the first sodium-glucose co-transporter-2 
inhibitor (SGLT-2) approved by the European Medicines Association, and positively 
assessed by the National Institute for Health and Care Excellence (NICE) for type 
2 diabetes mellitus (T2DM). This study evaluates the cost-effectiveness of dapagli-
flozin compared with a dipeptidyl-peptidase-IV (DPP-4) inhibitor when added to 
metformin in patients inadequately controlled on metformin alone. Methods: 
The published and validated CARDIFF diabetes model was used to conduct the 
analysis. Clinical inputs were derived from a systematic review and network meta-
analysis. Based on clinical inputs and the United Kingdom Prospective Diabetes 
Study (UKPDS) equations, the model predicts disease progression and the number 
of micro- and macro-vascular complications, along with diabetes-specific and all-
cause mortality. The perspective of the National Health Service in England and Wales 
was adopted over a lifetime horizon. Local unit costs and utility data were assigned 
to the appropriate model parameters to calculate total Quality-Adjusted-Life-Years 
(QALYs) and costs. Univariate and probabilistic sensitivity analyses (PSA) were con-
ducted. Results: Compared to a DPP-4 inhibitor, dapagliflozin was associated with 
0.076 incremental QALYs (95%CI: –0.028; 0.146) at an additional cost of £412 (95%CI: 
-£212; £853); resulting in an incremental cost-effectiveness ratio (ICER) of £5,455 
per QALY gained. The univariate analyses showed that no input parameter change 
inflated the ICER above £15,000 per QALY. The PSA estimated that dapagliflozin 
has a 81% chance to increase QALYs and costs, a 9% chance to increase QALYs 
and save costs, a 4% chance to reduce QALYs and costs and a 6% chance to reduce 
QALYs and increase costs. At a willingness-to-pay threshold of £20,000 per QALY 
gained, dapagliflozin strategy had an 86% probability to be cost-effective in this 
setting. ConClusions: Dapagliflozin in combination with metformin was shown 
to be a cost-effective treatment option for T2DM patients who are inadequately 
controlled with metformin mono-therapy.
PDB55
sources of long-term QuAlIty ADjusteD lIfe yeAr (QAly) gAIns for 
cAnAglIflozIn (cAnA) versus sItAglIPtIn (sItA) In the treAtment of 
tyPe 2 DIABetes mellItus (t2Dm) In the uK settIng
Willis M.1, Johansen P.1, Schroeder M.2, Thompson G.2, Girod I.2, Neslusan C.3
1The Swedish Institute for Health Economics, Lund, Sweden, 2Janssen UK, High Wycombe, UK, 
3Janssen Global Services LLC, Raritan, NJ, USA
objeCtives: The NICE reference case for T2DM requires cost-utility analysis with a 
lifetime horizon. The denominator in cost-utility outcomes is the incremental QALY, 
which is driven in most T2DM economic models by several key features, includ-
ing: life extension, micro- and macrovascular events, treatment and treatment-
related adverse events (AEs), and excess bodyweight. The aim of this analysis is to 
determine which factors most impact QALY gains in an analysis of CANA 300mg 
versus SITA 100mg when combined with metformin and sulphonylurea in the UK 
treatment setting. Methods: The ECHO-T2DM model was used to simulate CANA 
versus SITA over 40 years. ECHO-T2DM was loaded with patient characteristics, 
treatment effects, and AE rates from the DIA3015 trial. HbA1c was assumed to drift 
upwards at an annual rate of 0.14% for CANA and SITA (similar to metformin in 
the ADOPT trial). CANA and SITA were discontinued and insulin initiated (annual 
drift 0.15% as in UKPDS) when patients failed to maintain HbA1c under 58 mmol/
mol (7.5%). Results: Hypothetical patients experienced 0.039 more QALYs when 
treated with CANA 300mg versus SITA 100mg. Because SITA had lower initial HbA1c 
lowering, it was associated with greater use of rescue medication. Patients treated 
initially with SITA, thus, had greater insulin-mediated HbA1c lowering over time so 
HbA1c values converged asymptotically (limiting differences in rates of microvas-
cular complications). There were relatively modest QALY benefits related to macro-
Carlo simulation techniques to describe the long-term incidence and progression 
of diabetes-related complications. It was used to simulate disease progression in 
a cohort of pediatric patients with baseline characteristics taken from published 
KAZAKHSTAN studies (mean age 10.4 years, duration of diabetes 4.1 years, mean 
HbA1c > 7.5%). Direct costs for 2013 were calculated from a third-party payer per-
spective. Discount rates of 5% per annum were applied to costs and 3% to clinical 
outcomes. Results: Mean undiscounted life expectancy of patients using CSII vs. 
MDI was increased by 3.58 years. The Incremental-Cost-Effectiveness-Ratio (ICER) 
for CSII was 3,935,375KZT per Quality-Adjusted-Life-Year gained based on direct 
costs only. CSII related therapy costs were partially offset by the savings due to the 
reduction in long-term complications, i.e.638,744KZT, mainly due to cardiovascu-
lar and renal diseases. Cumulative incidences of proliferative diabetic retinopathy, 
blindness, ESRD, and GRP were decreased by 25.3%, 5.6%, 28.3%, and 17.7%, respec-
tively. CSII treatment also delayed the average onset of ESRD (3.9 years), blindness 
(3.7 years), PVD (3.5 years), CHF (3.6 years), Neuropathy (3.4 years), first ulcer (4.0 
years), amputation (3.7 years), MI (3.5 years), and stroke (3.5 years). Extensive sensi-
tivity analyses showed the robustness of the results. ConClusions: Using a payer’s 
perspective, our analysis showed that CSII is cost-effective over a lifetime horizon 
in children with Type 1 Diabetes in Kazakhstan (using a WTP threshold of 6,330,000 
KZT [3x GDP]) and can lead to an increase in life expectancy as well as delay and 
reduce long-term complications. When including indirect costs, CSII would be even 
more attractive from a societal perspective.
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objeCtives: To assess the cost-effectiveness of using intralesional injection of 
recombinant human epidermal growth factor (rhEGF) for the treatment of severe 
non-healing diabetic foot ulcers (DFU) in highly-specialized inpatient department 
in Russian setting. Methods: We developed a cost-effectiveness model based on 
hypothesis that use of intralesional injection of rhEGF in addition to standard treat-
ment of severe DFU (Wagner grade 3-4) would reduce the rate of amputations and 
related increased mortality in population of amputated DFU patients. For model 
inputs we used published data on the rates of amputation from retrospective study 
of intralesional injection of rhEGF and survival rates for patients with DFU with and 
without major amputations. Cost data was derived from the Russian retrospective 
study of real practice of inpatient treatment of severe DFU and reimbursement rates 
in Russian compulsory medical insurance system, cost of rhEGF treatment was pro-
vided by the manufacturer. Based on the model outputs we calculated incremental 
cost-effectiveness ratio (ICER) as the difference in costs to the difference in years 
lived during the 5-year period of observation by two cohorts of patients treated with 
only standard methods and with addition of rhEGF. Results: The use of rhEGF 
intralesional injection treatment may prevent 52 amputations and save 29.54 years 
of life in a cohort of 100 patients with severe DFU during subsequent 5-year period of 
observation. The ICER for rhEGF is estimated at EURO 27,200 per life year saved and 
does not exceed the acceptable threshold of three GDP per capita as recommended 
by WHO. The sensitivity analysis demonstrated that the results are most sensitive 
to the cost of rhEGF. ConClusions: The model has demonstrated the acceptability 
of adoption of intralesional injection of rhEGF in addition to standard treatment for 
DFU in highly specialized inpatient departments.
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objeCtives: To assess the cost-effectiveness of oral hypoglycaemic agents (micro-
nized glibenclamide, gliclazide, glimepiride and repaglinide) in the treatment of 
Russian patients with type 2 diabetes mellitus. Methods: Based on the data from 
comparative studies (B. Wolffenbuttel et al., 1999; A. Holstein et al., 2001; O. Reshetko 
et al., 2007) the pharmacoeconomic profiles of glibenclamide and repaglinide, gliben-
clamide and glimepiride, glibenclamide and gliclazide were compared. It was revealed 
that glibenclamide and repaglinide, glibenclamide and gliclazide have equal efficacy 
and safety, so the cost-minimization analysis was performed. The cost-effective-
ness of glibenclamide and glimepiride was measured as total costs of medicines 
and expenses for ambulance calls for severe hypoglycemia per one patient without 
hypoglycaemic events. A one-year time horizon was adopted in the models. One-
way sensitivity analysis (SA) was carried out to assess the robustness of the results 
. Results: Compared to repaglinide and gliclazide, treatment with glibenclamide 
was associated with substantial budget savings (22,699.35 RUB and 3,566.05 RUB per 
one patient, respectively). Costs per one patient without hypoglycaemic events were 
1,137.17 RUB and 5,549.85 RUB in glibenclamide and glimepiride groups, respectively. 
Sensitivity analysis demonstrated that results are robust. ConClusions: The pre-
sent study has demonstrated that administration of micronized glibenclamide is 
the most economically effective strategy in the treatment of Russian patients with 
type 2 diabetes mellitus. Treatment with micronized glibenclamide is associated 
with considerably lower costs as compared to repaglinide, glimepiride and gliclazide.
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